Literature DB >> 9784991

Flow-cytometric algorithm on fine-needle aspirates for the clinical workup of patients with lymphadenopathy.

I M Zardawi1, S Jain, G Bennett.   

Abstract

To analyze the value and limitations of flow cytometry (FCM) in the investigation of patients with lymphadenopathy, a retrospective study of 196 patients, referred for fine-needle aspiration (FNA) cytology, was carried out in Canberra, Australian Capital Territory, Australia, between 1992-1997. Complete cytological, flow-cytometric, and outcome (clinical and histological) data were available on all the cases. The FNA appearances were read in conjunction with FCM findings. The following cytological categories were recognized: benign, 78 cases (39.8%); indeterminate, 9 cases (4.6%); and malignant, 109 cases (55.6%). None of the 78 cytologically benign cases had malignant outcome. All 109 cytologically malignant cases had malignant histology, and 8/9 of the cytologically indeterminate FNAs had malignant histology. The cytologically malignant category contained 106 B-cell lymphomas and three T-cell lymphomas. All 65 B-cell lymphomas with K light chain predominance had K/L ratio greater than 3/1, and all 34 B-cell lymphomas with L light chain predominance had an L/K ratio greater than 2/1. Clonality was therefore established for K/L and L/K at 3/1 and 2/1, respectively. When K/L and L/K ratios were below these figures (7 cases), other parameters, including the proportion of CD20 and the dual expression of CD19/CD10 and CD20/CD5, were used to determine the nature of the aspirate. In the B-cell lymphomas without demonstrable light chain restriction, CD20 positivity in excess of 85%, CD19/CD10 positivity of more than 18%, or CD20/CD5 positivity greater than 35% were independently diagnostic of B-cell lymphoma. In the T-cell lymphomas, greater than 90% of the cells were T cells, and aberrant T-cell antigen expression with loss of at least one pan-T-cell antigen was detected. In conclusion, the sensitivity of diagnosis of malignancy, false-negative rate, and predictive value of malignant diagnosis with combined FNA cytology and FCM were 99%, 0%, and 100%, respectively.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9784991     DOI: 10.1002/(sici)1097-0339(199810)19:4<274::aid-dc9>3.0.co;2-a

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  5 in total

1.  Immunophenotypic profiles for distinguishing orbital mucosa-associated lymphoid tissue lymphoma from benign lymphoproliferative tumors.

Authors:  Shunichiro Ueda; Yoshihiko Usui; Takeshi Nagai; Daniel Diaz-Aguilar; Toshitaka Nagao; Hiroshi Goto
Journal:  Jpn J Ophthalmol       Date:  2017-04-18       Impact factor: 2.447

2.  Immunoflow cytometry and cell block immunohistochemistry in the FNA diagnosis of lymphoma: a review of 73 consecutive cases.

Authors:  F Mayall; M Dray; D Stanley; B Harrison; R Allen
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

3.  Combined applications of fine needle aspiration cytology and flow cytometric immunphenotyping for diagnosis and classification of non Hodgkin lymphoma.

Authors:  Pranab Dey; Thasneem Amir; Aisha Al Jassar; Salem Al Shemmari; Sanjay Jogai; Ganapathi Bhat M; Aisha Al Quallaf; Zahia Al Shammari
Journal:  Cytojournal       Date:  2006-10-27       Impact factor: 2.091

4.  Flow cytometric immunophenotyping and cell block immunocytochemistry in the diagnosis of primary Non-Hodgkin's Lymphoma by fine-needle aspiration: Experience from a tertiary care center.

Authors:  Tuhin Paul; Upasana Gautam; Arvind Rajwanshi; Ashim Das; Amita Trehan; Pankaj Malhotra; Radhika Srinivasan
Journal:  J Cytol       Date:  2014-07       Impact factor: 1.000

5.  Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas?

Authors:  Andreja Brozic; Ziva Pohar Marinsek; Srdjan Novakovic; Veronika Kloboves Prevodnik
Journal:  Diagn Pathol       Date:  2015-10-20       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.